EGFR and glioblastoma: GBM often exhibits five genetic mutations that are viewed as molecular markers for identification and prognosis: (1) IDH mutation status; (2) O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status; (3) Epidermal Growth Factor Receptor (EGFR) amplification; (4) chromosome 7 gain and chromosome 10 loss; and (5) Telomerase Reverse Transcriptase (TERT) promoter mutations [1,3].